Fennec Pharmaceuticals Inc.
fennecpharma.comWhat Do They Do?
Sells PEDMARK, an intravenous medicine used by pediatric oncology providers to reduce cisplatin-related hearing loss in children with localized, non-metastatic solid tumors.
10-K for FY2025, filed Mar 27, 2026Fennec Pharmaceuticals Inc., a corporation existing under the laws of British Columbia, was originally formed under the name Adherex…View ↗
PEDMARK® is currently the only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric…View ↗
In the United States, we sell our product through an experienced field force including Regional Pediatric Oncology Specialists and we…View ↗
How Do They Make Money?
Fennec earns U.S. product-sale revenue from PEDMARK, supplies product under a partner distribution agreement in Turkey and GCC countries, and receives licensing consideration from Norgine upfront, with possible future milestone payments and royalties tied to net sales.
10-K for FY2025, filed Mar 27, 2026Since our formation in September 1996, we have engaged in research and development programs. We have recently begun to generate revenue…View ↗
In 2025, we entered into a distribution agreement with Inpharmus for the commercialization of PEDMARK® in Turkey and the GCC countries.…View ↗
Under the terms of the licensing agreement, Fennec received approximately $43 million in upfront consideration and may receive up to…View ↗
$44.6M
-
10-K for FY2025, filed Mar 27, 2026
$44.6M ↗
Who Are Their Customers?
Fennec sells PEDMARK in the U.S. through its field force and through distributors. Norgine commercializes PEDMARQSI in Europe, Australia and New Zealand, while Inpharmus handles distribution and some commercialization in Turkey and GCC countries.
10-K for FY2025, filed Mar 27, 2026In the United States, we sell our product through an experienced field force including Regional Pediatric Oncology Specialists and we…View ↗
For the years ended December 31, 2025 and 2024, the Company had three distributors that represented more than 10% of net sales.View ↗
As previously noted, in March 2024, we entered into an agreement with Norgine, a leading European specialist pharmaceutical company. This…View ↗
Under the terms of the licensing agreement, Fennec received approximately $43 million in upfront consideration and may receive up to…View ↗
In 2025, we entered into a distribution agreement with Inpharmus for the commercialization of PEDMARK® in Turkey and the GCC countries.…View ↗
Do Revenues Turn Into Profits?
No. It lost $9.7M in FY2025.
10-K for FY2025, filed Mar 27, 2026
How Are They Changing?
Partner-led international commercialization
The latest report describes European and U.K. approvals and partner-led commercialization, plus a distribution agreement covering Turkey and GCC countries; the older report described U.S. sales and a pending European application.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 27, 2026We are a commercial-stage biopharmaceutical company focused on our only product candidate PEDMARK®. On September 20, 2022, we received…View ↗
We sell our product through an experienced field force including Regional Pediatric Oncology Specialists and medical science liaisons who…View ↗
European Marketing Authorization ApplicationView ↗
PEDMARQSI® (PEDMARK® brand name in Europe) received European Commission Marketing Authorization in June 2023 and received U.K. approval in…View ↗
As previously noted, in March 2024, we entered into an agreement with Norgine, a leading European specialist pharmaceutical company. This…View ↗
In 2025, we entered into a distribution agreement with Inpharmus for the commercialization of PEDMARK® in Turkey and the GCC countries.…View ↗
Who Do They Compete With?
Competes with Sound Pharmaceuticals and Decibel Therapeutics
10-K for FY2025, filed Mar 27, 2026We are not aware of any commercially available agents that reduce the incidence of hearing loss associated with the use of platinum-based…View ↗
Loading...
